Literature DB >> 9639386

Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients.

C Asselin-Paturel1, H Echchakir, G Carayol, F Gay, P Opolon, D Grunenwald, S Chouaib, F Mami-Chouaib.   

Abstract

For understanding the local immune response in human non-small cell lung cancer (NSCLC), we investigated both Th1 and Th2-type as well as TGF-beta1 cytokine mRNA expression in 10 fresh tumor biopsies, the corresponding tumor and short term TIL cell lines as well as patient PBMC. A methodology based on a highly sensitive quantitative RT-PCR was used. We found that IL-6 mRNA was highly expressed in all tumor biopsy samples analyzed (4 LLC, 3 ADC and 3 SCC). IL-10 mRNA was expressed in 7 of 10 biopsies whereas IL-4 mRNA expression was moderate. Analysis of type I cytokines revealed a low expression level of IL-2 mRNA, while IFNgamma and GM-CSF expression was high in the majority of the tumor lesions studied. Quantitatively, high amounts of Th2-type cytokine mRNA were detected at the tumor site with IL-6 as the predominant lymphokine. A high mRNA expression level of the immunosuppressive cytokine TGF-beta1 was observed in all NSCLC. To identify the cell types responsible for the production of TGF-beta1, IL-6, IL-10 and GM-CSF at the tumor site, tumor and TIL cell lines were derived from the corresponding biopsies. All the 3 tumor cell lines analysed were found to express high amount of TGF-beta1 but not IL-10 mRNA, 2 expressing IL-6 and GM-CSF. Five short term TIL cell lines established in the presence of IL-2 expressed high level of IL-10, IL-4 and IFNgamma but not IL-2 mRNA. Strikingly, high expression of IL-10 mRNA was also observed in all 6 patient PBMC analyzed as compared to controls. Together, our results indicate the existence of a local and peripheral Th-2-type cytokine pattern in patients bearing NSCLC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639386     DOI: 10.1002/(sici)1097-0215(19980703)77:1<7::aid-ijc2>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Masatomo Miura; Yudai Hinai; Hajime Saito; Manabu Ito; Takashi Ono; Hiroshi Toda; Satoru Motoyama; Jun-ichi Ogawa
Journal:  Tumour Biol       Date:  2010-05-27

3.  Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer?

Authors:  Elizabeth S Evans; Zafer Kocak; Su-Min Zhou; Daniel A Kahn; Hong Huang; Donna R Hollis; Kim L Light; Mitchell S Anscher; Lawrence B Marks
Journal:  Cytokine       Date:  2006-09-18       Impact factor: 3.861

4.  Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.

Authors:  Soraya Abouzahr; Georges Bismuth; Catherine Gaudin; Oliver Caroll; Peter Van Endert; Abdelali Jalil; Jean Dausset; Isabelle Vergnon; Catherine Richon; Audrey Kauffmann; Jérôme Galon; Graca Raposo; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

6.  Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.

Authors:  L Wang; H Yang; Z Lei; J Zhao; Y Chen; P Chen; C Li; Y Zeng; Z Liu; X Liu; H-T Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

7.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.

Authors:  F M Brichory; D E Misek; A M Yim; M C Krause; T J Giordano; D G Beer; S M Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  PDLIM5 inhibits STUB1-mediated degradation of SMAD3 and promotes the migration and invasion of lung cancer cells.

Authors:  Yueli Shi; Xinyu Wang; Zhiyong Xu; Ying He; Chunyi Guo; Lingjuan He; Caijuan Huan; Changhong Cai; Jiaqi Huang; Jie Zhang; Yiqing Li; Chunlai Zeng; Xue Zhang; Linrun Wang; Yuehai Ke; Hongqiang Cheng
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

9.  Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer.

Authors:  Rui Li; Dominik Rüttinger; Rong Li; Lü-Sheng Si; Yi-Li Wang
Journal:  Langenbecks Arch Surg       Date:  2003-09-19       Impact factor: 3.445

10.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Authors:  Hamid Echchakir; Guillaume Dorothée; Isabelle Vergnon; Jeanne Menez; Salem Chouaib; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.